Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease
- 9 June 2021
- journal article
- research article
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 4 (3), 275-282
- https://doi.org/10.3138/canlivj-2021-0004
Abstract
BACKGROUND: With the rate of non-alcoholic fatty liver disease (NAFLD) on the rise, the necessity of identifying patients at risk of cirrhosis and its complications is becoming ever more important. Liver biopsy remains the gold standard for assessing fibrosis, although costs, risks, and availability prohibit its widespread use with at-risk patients. Transient elastography has proven to be a non-invasive and accurate way of assessing fibrosis, although the availability of this modality is often limited in primary care settings. The Fibrosis-4 (FIB-4) and Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) are scoring systems that incorporate commonly measured lab parameters and BMI to predict fibrosis. METHOD: In this study, we compared FIB-4 and NFS scores with transient elastography scores to assess the accuracy of these inexpensive and readily available scoring systems in detecting fibrosis. RESULTS: Using an NFS score cut-off of -1.455 and a FibroScan score cut-off of >= 8.7 kPa, the NFS score had a negative predictive value of 94.1%. Using a FibroScan score cut-off of >= 8.7 kPa, the FIB-4 score had a negative predictive value of 91.6%. CONCLUSION: The NFS and FIB-4 are non-invasive, inexpensive scoring systems that have high negative predictive value for fibrosis compared with transient elastography scores. These findings suggest that the NFS and FIB-4 can provide adequate reassurance to rule out fibrosis in patients with NAFLD and can be used with select patients to circumvent the need for transient elastography or liver biopsy.Keywords
This publication has 20 references indexed in Scilit:
- The epidemiology of non‐alcoholic fatty liver diseaseLiver International, 2017
- Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosisHepatology International, 2015
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and OutcomesClinical Gastroenterology and Hepatology, 2015
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United StatesGastroenterology, 2015
- Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significanceWorld Journal of Gastroenterology, 2015
- Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008Clinical Gastroenterology and Hepatology, 2011
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adultsAlimentary Pharmacology & Therapeutics, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic SteatohepatitisGastroenterology, 2008
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort StudyGastroenterology, 2005